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Background: The Consolidated Standards for Reporting Trials (CONSORT) are aimed to standardize clinical trial
reporting. Our objective is to compare the quality of randomized clinical trials (RCTs) of traditional Chinese
medicine (TCM) published in 2005–2009 and 2011–2012 according to the current CONSORT statements and Jadad
scale.
Methods: Data Sources: Reports on RCTs of TCM in the China National Knowledge Infrastructure database (CNKI
database) for manuscripts published from 2005 to 2009 and 2011–2012. Search terms included TCM and clinical
trial. Study Selection: Manuscripts that reported RCTs of TCM were included. Data Extraction: Independent
extraction of articles was done by 3 authors. Disagreement was discussed until agreement was reached. According
to the CONSORT checklist, an item was scored as 1 when the item was described in the paper. Otherwise the item
was scored as 0.
Results: A total of 4133 trials in 2005–2009 and 2861 trials in 2011–2012 were identified respectively. There was a
significant increase in proportion of reports that included details of background (24.71% vs 35.20%, P < 0.001),
participants (49.79% vs 65.26%, P < 0.001), the methods of random sequence generation (13.77% vs 19.85%,
P < 0.001), statistical methods (63.00% vs 72.77%, P < 0.001) and recruitment date (70.14% vs 80.36%, P < 0.001) in
2011–2012 compared to 2005–2009. However, the percentage of reports with trial design decreased from 4.45% to
3.25% (P = 0.011). Few reports described the blinding methods, and there was a decreasing tendency (4.77% vs
2.48%, P < 0.001). There was a similar decreasing tendency on the reporting of funding (6.53% vs 5.00%, P = 0.007).
There were no significant differences in the other CONSORT items. In terms of Jadad Score, the proportion of
reports with a score of 2 was markedly increased (15.15% vs 19.71%, P < 0.001).
Conclusions: Although the quality of reporting RCTs of TCM was improved in 2011–2012 compared to 2005–2009,
the percentages of high-quality reports are both very low in terms of Jadad score. There is a need for improving
standards for reporting RCTs in China.
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In order to acquire effective and credible outcomes,
randomization and control are essential for clinical trials.
Randomized controlled trials (RCTs) provide the most
reliable evidence of health care intervention and are the
basis for the establishment of many medical guidelines.
However, RCTs are not always reported with sufficient
details or clarity, potentially hindering interpretation of
results [1,2]. For a reader to accurately evaluate the con-
clusion of a published report, he (she) needs complete,
clear, and transparent information on the methodology
and findings of the report. Unfortunately, attempted as-
sessments frequently fail because authors of many trial
reports do not describe some critical data and only lim-
ited information is available [3-5].
The CONSORT (consolidated standards of reporting
trials) statement was first published in 1996, revised in
2001 and updated in 2010 by the CONSORT Group. They
provide authors and editors with a checklist for a mini-
mum set of recommendations for reporting the trial de-
sign, analysis and results [6-8]. Many studies have showed
that quality of trial reporting can be improved when au-
thors follow the checklist of the CONSORT [9-12]. The
Jadad score is considered a valid and reliable tool to assess
the methodological quality of a clinical trial, and has been
applied throughout the medical literature [13,14].
Traditional Chinese medicine (TCM), including herbal
medicine, are widely used in China to treat a variety of dis-
eases and used increasingly to complement conventional
medical care globally. In a nationally representative U.S.
survey conducted in 2002, almost 20% of adults and 75%–
100% of Asian-Americans had used herbal therapies in the
past year [15]. They believe the TCM and conventional
medicine provides more optimal healing than conven-
tional medicine alone [16-18]. However, in the era of
evidence-based medicine, TCM has encountered a strong
challenge from clinicians due to a shortage of evidence-
based efficacy. Therefore, researchers have made a great
deal of effort in TCM clinical studies. In the past decade,
TCM RCT is avocated and a number of RCTs of TCM
have been reported [19-23]. Recently many TCM re-
searchers evaluated the quality of RCTs with TCM accord-
ing to the checklist of the CONSORT [24-29]. Their
studies show that the quality of TCM RCTs is generally
low. However, these studies evaluated only one or several
TCM journals, or evaluated publication on a specific
disease. Thus they cannot give a comprehensive view on
the overall quality of TCM RCTs.
The purpose of the present study was to compare the
change in quality of reporting TCM RCTs prior to and
after the publication of the 2010 CONSORT statement.
We include all publications of TCM RCTs during this
period in the CNKI database, aiming to comprehensively
evaluate the overall quality of TCM RCTs.Methods
Search strategy
The China National Knowledge Infrastructure (CNKI)
database is the most comprehensive full-text database of
journals published in China and was used in the present
study [30]. The CNKI database has several subdatabases.
Among them is the academic journals’ full-text database,
which was used in the present study. We chose manu-
scripts published in 2005–2009 and 2011–2012, which
respectively represent publications before and after the
2010 CONSORT statement. We used an electronic
search strategy that involved subject term ‘traditional
Chinese medicine’ and ‘clinical trial’ and “Fuzzy Search”
method so as to acquire more potential manuscripts. To
evaluate the tendency of publication quality, we evalu-
ated the published reports on an annual base. The titles,
index terms, and abstracts of the identified manuscripts
were read and rated as “potential manuscript” or “not
relevant”. We retrieved all potential manuscripts and
reviewed their full texts according to the following
criteria:
Inclusion criteria were manuscripts reporting TCM
RCTs.
Exclusion criteria were (1) review, literature analysis,
experience, case report; (2) animal experiments; (3)
Non-randomized clinical trials; (4) reduplicative report-
ing; (5) retrospective study; (6) others. Three reviewers
(J L, Z L, R C) reviewed the texts of the manuscripts to
identify TCM RCTs. Disagreements regarding inclusion
were resolved by discussion. Figure 1 shows the process
of collecting materials and analysis.
Scoring according to CONSORT
A checklist of 25 items from the updated 2010 CON-
SORT guidelines was used [31-33]. Among the 25 items,
12 have 2 subitems. The score for each item or subitem
was either 0 or 1: 0 indicates no description of the corre-
sponding item/subitem and 1 indicates there was de-
scription of the item/subitem in the report. We did not
include the following subitems in our report because we
found after analysis of all manuscript that (1) there were
no reports that changed the methods after trial com-
mencement (Subitem 3b); (2) there were no reports that
changed trial outcomes after the trial commenced (Subi-
tem 6b); (3) there were no reports that had interim ana-
lyses and stopping guidelines (Subitem 7b); (4) there
were no reports that were stopped prematurely (Subitem
14b); (5) there were no reports that had additional
analyses (Subitem 18). After these 5 subitems were
excluded, the maximum score a paper could obtain 31
points. Each article was assessed for every item accord-
ing to the checklist [29] by three investigators independ-
ently (J L, Z L and R C). When there were different
opinions between three investigators, they discussed
Figure 1 The process of collecting materials.
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cision was made by L L. The total score of each trial was
calculated.
Scoring according to Jadad
The Jadad scale is a 5-point scale for measuring the quality
of randomized trials. A score of three points or more in-
dicates high quality [13]. The Jadad scale includes how
generation of random sequence is described (0 = no de-
scription; 1 = inadequate description; 2 = adequate descrip-
tion); how the blinding is carried out (2 = double-blinding
with adequate description; 1 = double-blinding with inad-
equate description; 0 = wrong usage of double-blinding),
and why and how often withdrawal of patients happensTable 1 Results of screening for randomized clinical trials fro
2005 2006
Records identified through database searching 2040 2142
Duplicated papers 3 6
Reviews 347 387
Experience 148 146
Literature analysis 30 36
Animal experiments 22 20
Not randomized 512 540
Retrospective study 3 13
Case report 20 38
Others 244 257
Full-text articles assessed for eligibility 711 699
Studies included in final review 711 699(When the numbers and reasons of withdrawal and exit of
patients were reported, we recorded 1. Otherwise, 0 was
recorded). Similarly, the work was done by three investiga-
tors (J L, Z L and R C) separately. Disagreement was dis-
cussed by three until agreement was reached. Otherwise
final decision was made by L L.
Statistics
Pearson χ2 test was used to test whether differences
among two periods (2005–2009 and 2011–2012) were
statistically significant in terms of mean total score of
CONSORT. Wilcoxon rank sum test was used to test
differences of Jadad scores of the different years. The
levels of significance for all tests were set at 0.05. Data
were analyzed using SPSS version 18.0. The total score
of each report and the percentage of different score were
calculated.
Results
Characteristics of selected RCTs
After screening the titles, abstracts and texts, we identified
a total of 4133 reports in 2005–2009 and 2861 in 2011–
2012 in the CNKI database that met the inclusion and
exclusion criteria and were included in this analysis. The
annual numbers of reports identified in each screening
step are shown in Table 1.
The CONSORT results
CONSORT: title, abstract, background and objectives
The proportion of reports with “randomized” in the title
(1a) increased significantly (0.56% vs 1.15%, P = 0.006).
However, the percentages were very low for both periods
(Table 2 and Figure 2). 84.81% of reports had abstracts
(1b) that included objective, methods, results and con-
clusions in 2005–2009, more than that in 2011–2012
(82.03%). The proportions of reports with detailed de-
scription of backgrounds (2a) of studies were low form 2005 to 2012
2007 2008 2009 2011 2012
2795 3595 3706 6072 5874
6 22 80 24 83
609 773 717 1176 1255
209 242 275 785 530
26 39 59 93 72
17 20 18 15 12
648 679 772 1083 1076
16 25 17 23 86
47 80 77 189 156
548 704 648 1342 1085
669 1011 1043 1342 1519
669 1011 1043 1342 1519
Table 2 Comparision of randomized control trials indexed in CNKI database before and after 2010 in terms of
CONSORT items
Criterion Item no. No. (%) of trials in which the item was clearly reported P value
All (n = 6994) Before 2010 (n = 4133) After 2010 (n = 2861)
Title and abstract 1a 56 (0.80) 23 (0.56) 33 (1.15) 0.006
1b 5852 (83.67) 3505 (84.81) 2347 (82.03) 0.002
Background and objectives 2a 2028 (29.00) 1021 (24.71) 1007 (35.20) <0.001
2b 410 (5.86) 263 (6.36) 147 (5.14) 0.032
Trial design 3a 277 (3.96) 184 (4.45) 93 (3.25) 0.011
Participants 4a 3925 (56.12) 2058 (49.79) 1867 (65.26) <0.001
4b 4938 (70.60) 2664 (64.46) 2274 (79.48) <0.001
Interventions 5 5699 (81.48) 3342 (80.86) 2357 (82.38) 0.107
Outcomes 6a 6176 (88.30) 3626 (87.73) 2550 (89.13) 0.074
Sample size 7a 20 (0.29) 8 (0.19) 12 (0.42) 0.082
Sequence generation 8a 1137 (16.26) 569 (13.77) 568 (19.85) <0.001
8b 117 (1.67) 78 (1.89) 39 (1.36) 0.093
Allocation concealment mechanism 9 48 (0.69) 30 (0.73) 18 (0.63) 0.63
Implementation 10 36 (0.51) 31 (0.75) 5 (0.17) 0.001
Blinding 11a 268 (3.83) 197 (4.77) 71 (2.48) <0.001
11b 8 (0.11) 5 (0.12) 3 (0.10) 1.000
Statistical methods 12a 4686 (67.00) 2604 (63.00) 2082 (72.77) <0.001
Flow diagram 13a 20 (0.29) 11 (0.27) 9 (0.31) 0.709
13b 246 (3.52) 141 (3.41) 105 (3.67) 0.564
Recruitment 14a 5198 (74.32) 2899 (70.14) 2299 (80.36) <0.001
Baseline data 15 445 (6.36) 232 (5.61) 213 (7.44) 0.002
Numbers analyzed 16 127 (1.82) 80 (1.94) 47 (1.64) 0.367
Outcomes and estimation 17a 89 (1.27) 58 (1.40) 31 (1.08) 0.241
17b 21 (0.30) 8 (0.19) 13 (0.45) 0.050
Harms 19 1830 (26.17) 1096 (26.52) 734 (25.66) 0.42
Limitations 20 572 (8.18) 356 (8.61) 216 (7.55) 0.11
Generalizability 21 187 (2.67) 115 (2.78) 72 (2.52) 0.498
Interpretation 22 6473 (92.55) 3806 (92.09) 2667 (93.22) 0.077
Registration 23 1 (0.01) 0 (0) 1 (0.03) 0.853
Protocol 24 1 (0.01) 0 (0) 1 (0.03) 0.853
Funding 25 413 (5.91) 270 (6.53) 143 (5.00) 0.007
Li et al. BMC Complementary and Alternative Medicine 2014, 14:362 Page 4 of 11
http://www.biomedcentral.com/1472-6882/14/362both periods, but were higher in 2011–2012 (24.71% in
2005–2009 vs 35.20% in 2011–2012, P < 0.001). The
proportions of reports with objectives (2b) were also low
(6.36% vs 5.14%, P = 0.032) (Table 2).
CONSORT: materials and methods
Description on the following items had obvious improve-
ment in 2011–2012 over 2005–2009: inclusion and exclu-
sion criteria of patients (4a) (65.26% vs 49.79%, P < 0.001),
the place of collecting materials (4b) (79.48% vs 64.46%,
P < 0.001). However, the proportions on the description
of the patient distribution (3a) decreased (P = 0.011).Although the proportions on the description of interven-
tions, outcomes and the calculated sample size were im-
proved, there was no significant difference (Table 2). As
shown in Figure 3, there is a fluctuation in the proportions
on the description of these items during 2005–2012.
CONSORT: randomization
Description on sequence generation (8a) also increased
significantly (13.77% in 2005–2009 vs 19.85% in 2011–
2012, P < 0.001). However, the proportion of reports with
blinding (11a) decreased in 2011–2012 (4.77% in 2005–
2009 vs 2.48% in 2011–2012, P < 0.001). Similar trend
Figure 2 CONSORT results of title, abstract, background and objectives in each year.
Figure 3 CONSORT results of materials and methods in each year.
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process (10) (0.75% vs 0.17%, P = 0.001). Few reports
described the allocation concealment mechanism (9)
(Table 2). As shown in Figure 4, there is a fluctuation in
the proportions on the description of these items from
2005 to 2012.CONSORT: results
The proportion with detailed statistical methods (12a)
was greater after 2010 (63.00% in 2005–2009 vs 72.77%
in 2011–2012, P < 0.001). The proportion of reports with
the dates of recruiting and follow-up (14a) was greater
after 2010 (70.14% in 2005–2009 vs 80.36% in 2011–
2012, P < 0.001). Although the proportion of papers that
reported loss to follow-up (13b) and flow diagram (13a)
increased after 2010, the quality remained to be im-
proved. The proportion of reports with baseline data de-
scription (15) increased (P= 0.002), (Table 2). As shown
in Figure 5, there is a fluctuation in the proportions of
reports with the description of these items from 2005 to
2012 except recruiting and follow-up (14a).Figure 4 CONSORT results of ‘randomization’ in each year.CONSORT: discussion
There was no difference in proportions of papers report-
ing harms (19), limitations (20), generalizability (21) and
interpretation (22) before and after 2010 (Table 2). As
shown in Figure 6, there is a fluctuation in the proportions
on the description of these items from 2005 to 2012.
CONSORT: other information
Only one paper reported the registration (23) or the
protocol (24). The proportion of paper reporting fundings
(25) decreased markedly during 2011–2012 compared to
2005–2009 (P = 0.007) (Table 2).
CONSORT: total score of each report
Figure 7 shows the distribution of the mean scores of re-
ports before and after 2010, with 24 being the highest score.
The scores range from 1 to 24, with most of them within
the range of 4–11. Generally the scores of reports are low
for both periods and the mean score of 2011–2012 is
slightly higher (7.09 in 2005–2009 vs 7.70 in 2011–2012)
(Figure 8). Figure 9 shows that the annual distributions of
the reports with a specific score in each year are similar.
Figure 5 CONSORT results of ‘results’ in each year.
Figure 6 CONSORT results of ‘discussion’ in each year.
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Figure 7 The distribution of the mean scores before and after 2010.
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There are very few papers with a score above 2. The
mean scores of reports are similar for both periods (1.22
for 2005–2009 vs 1.25 for 2011–2012, P = 0.405, Figure 10).
The annual mean scores are similar from 2005 to 2012
(P = 1.000, Figure 11).
Discussion
In the present study, we demonstrate that proportions of
reports with descriptions of CONSORT items 1a, 2a, 4a,
4b, 8a, 12, 14a, 15 and 17b increase after 2010, while
proportions of reports with descriptions of CONSORT
items 1b, 2b, 3a, 10, 11a, and 25 decrease after 2010.
And for most of the items, there is a fluctuation of pro-
portion on description of the item from 2005 to 2012.
These data indicate that publication of CONSORT has
little, if any, influence on the most of the researchers
reporting clinical trials in China.
TCM has been practiced in China for thousands of
years. TCM doctors use herbal medicine to treat a var-
iety of diseases. The medical herbs may be used singly
or in combination. In the past decades, the effects of
TCM have been evaluated in various animal models and
the underlying mechanisms have also been explored in
cellular, protein or DNA levels. Nevertheless, the effi-
ciency of TCM should be demonstrated in RCTs, whichFigure 8 The mean score of publication of each year.is the top-level evidence for therapy. For example,
Chansu, the skin and parotid venom glands of Bufo bufo
gargarizans cantor, is a well-known TCM widely used
for the treatment of a variety of tumors in China [34,35].
Experimental studies suggested that Chansu and its ac-
tive compounds exhibit significant anti-tumor activity
via inhibiting cell proliferation, inducing apoptosis and
cell arrest and inhibiting angiogenesis [36]. Further stud-
ies demonstrated that bufalin, one compound in Chansu,
induced apoptosis of gastric cancer cells by inhibition of
AKT signaling pathway [37] and inhibiting proliferation
of hepatocellular carcinoma cells through inhibiting AKT/
GSK3β/β-catenin/E-cadherin signaling pathway [38].
RCTs for TCM were first published in the 1980s [39].
Since then, a number of TCM RCTs have been published.
However, the quality of the reports of the TCM RCTs were
poor [39-44]. For example, Fang et al. reported that only
13 trials in 338 RCTs reports had the detailed description
on method of randomization [40]. In the present study,
we identified that only 8 of 31 CONSORT items have sig-
nificant improvements from 2005–2009 to 2011–2012. A
detailed and informative introduction of background can
make readers understand the purpose of the study. De-
tailed inclusion and exclusion criteria of patients will avoid
the selection bias. Clear and definite description of inter-
vention is critical for the study to be repeated. In particular,
Figure 9 The annual distributions of the CONSORT score of reports.
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implications for assessment of internal validity [45]. We
found that 29.00% of the articles described the background
from 2005 to 2012. Sequence generation was described in
only 16.26% of the publications, blinding in 3.83% and cal-
culation of simple size in 0.29%. Inadequate description of
these items will make the results of the study incredible.
Another problem was there were only 56 out of 6994 re-
ports that had the term ‘randomize’ in their titles. Title is a
very important part of an article. Researchers use title to
screen potential studies in meta-analysis.
With regard to methodological items, calculation of
sample size was done by only 20 reports out of 6994 re-
ports. If the sample is too large, it would be a waste of
time and money. The smaller number of patients will re-
duce statistical power and generate selection bias. There
were 268 reports using blinding method. The proportion
of description on blinding method decreased after 2010.
Blinding, especially double-blinding, is challenging forFigure 10 The Jadad score before and after 2010. The scores of
reports are similar for both periods (2005–2009 vs 2011–2012, P= 0.405).studies in which the intervention is being randomized [46].
Inadequate measures to create and conceal the random al-
location, selective attrition, and insufficient double-blinding
have been theorized to bias the estimates of treatment ef-
fects in RCTs [47].
Reports on adverse events were obvious not detailed
enough, which will overestimate the safety of TCM. In fact,
the recorded information of TCM herbs in most classical
books includes toxicities, incompatibilities between herbs,
cautions, precautions and contraindications. Thus, con-
trary to a general misconception, toxicity data on Chinese
herbs exist and are documented through clinical experi-
ence [48]. For example, cinnabar, which contains mercury
sulfide, has been used in TCM for thousands of years and
40 cinnabar-containing traditional medicines are still used
today. Absorbed mercury from cinnabar is mainly accu-
mulated in the kidneys, resembling the disposition patternFigure 11 The annual distributions of the Jadad score of reprts.
The mean scores are similar from 2005 to 2012 (P =1.000)
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renal dysfunction may occur [49].
In addition, the reporting of outcomes and ancillary
analyses remained poor. For example, intention-to-treat
analysis is advocated because it preserves the randomization
process and allows for noncompliance and deviations from
policy by clinicians [50]. There are only 9 in 6994 papers
using intention-to-treat analysis.
Discussion is an important part of a report. The
author(s) can discuss the advantages and generalizability
of the treatment, as well as the limitations of the study
there. As we noticed, few reports have an informative
discussion (Table 2). Finally, only one report contained
information about registration, another one report
contained information of protocol.
According to Jadad scale, there were 188 reports which
scores were over 2 points. There was no difference be-
tween publications before and after 2010. Thus, report-
ing of TCM RCTs improved very slowly in their quality.
The average Jadad score was 1.25 during 2011–2012,
compared to 1.22 during 2005–2009.
In the present study we chose the CNKI database as
the database to avoid selection bias. The CNKI database
is the most comprehensive database in China. It achieves
the full-text publications of 1217 medical Chinese jour-
nals, including 26 journals for TCM and 18 for integra-
tive TCM and modern Western medicine. In addition,
two researchers assessed independently the quality of
each report by reading its full text. This is in sharp con-
trast to the previous reports, which evaluated only one
or several TCM journals, or evaluated publication on a
specific disease [24-29]. Thus the present study is the
most comprehensive one on TCM RCTs.
Interestingly, we found that none of the manuscripts de-
scribed change of the methods after trial commencement
(Subitem 3b), change of trial outcomes after the trial com-
menced (Subitem 6b), interim analyses and stopping
guidelines (Subitem 7b), premature discontinuation of the
trial (Subitem 14b) and additional analyses (Subitem 18).
The underlying reason is unknown.
Conclusions
Although some improvements have been made in
reporting TCM RCTs, the pace remains slow. And there
remains considerable room for further improvement.
The problems include optimal design of randomization,
the usage of blinding, the calculation of sample size,
comparability of baseline information, the clear and def-
inite inclusion and exclusion criteria, the usage of statis-
tical method, the withdrawal and follow-up of patients
and the records of adverse events. Doctors practicing
TCM should be trained to write high-quality reports and
active implementation of the CONSORT guidelines by
journals is necessary to make the reports on TCM RCTsmore credible and TCM be used more widely in the
world as an alternative medicine. We also suggest that a
bibliographic database of TCM RCTs, similar to Acu-
Trials(R), be developed to enhance the accessibility and
quality of TCM RCTs [51].
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